Cargando…
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717840/ https://www.ncbi.nlm.nih.gov/pubmed/31696051 http://dx.doi.org/10.2147/PTT.S161453 |
_version_ | 1783447623820115968 |
---|---|
author | Ly, Karen Beck, Kristen M Smith, Mary P Orbai, Ana-Maria Liao, Wilson |
author_facet | Ly, Karen Beck, Kristen M Smith, Mary P Orbai, Ana-Maria Liao, Wilson |
author_sort | Ly, Karen |
collection | PubMed |
description | Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the management of treatment resistant disease, and is reported to improve enthesitis, dactylitis, and radiographic progression. Tofacitinib is also associated with an increased risk of serious infections, malignancy, and laboratory abnormalities. There is currently a large armamentarium of therapies for psoriatic arthritis, and choosing among treatments can be challenging. Due to this wide selection, a thorough assessment of psoriatic disease phenotype, patient preference, disease presentation, and comorbidities is critical. This review addresses key considerations in patient selection for the treatment of PsA with tofacitinib. |
format | Online Article Text |
id | pubmed-6717840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67178402019-11-06 Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives Ly, Karen Beck, Kristen M Smith, Mary P Orbai, Ana-Maria Liao, Wilson Psoriasis (Auckl) Review Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the management of treatment resistant disease, and is reported to improve enthesitis, dactylitis, and radiographic progression. Tofacitinib is also associated with an increased risk of serious infections, malignancy, and laboratory abnormalities. There is currently a large armamentarium of therapies for psoriatic arthritis, and choosing among treatments can be challenging. Due to this wide selection, a thorough assessment of psoriatic disease phenotype, patient preference, disease presentation, and comorbidities is critical. This review addresses key considerations in patient selection for the treatment of PsA with tofacitinib. Dove 2019-08-28 /pmc/articles/PMC6717840/ /pubmed/31696051 http://dx.doi.org/10.2147/PTT.S161453 Text en © 2019 Ly et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Ly, Karen Beck, Kristen M Smith, Mary P Orbai, Ana-Maria Liao, Wilson Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives |
title | Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives |
title_full | Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives |
title_fullStr | Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives |
title_full_unstemmed | Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives |
title_short | Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives |
title_sort | tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717840/ https://www.ncbi.nlm.nih.gov/pubmed/31696051 http://dx.doi.org/10.2147/PTT.S161453 |
work_keys_str_mv | AT lykaren tofacitinibinthemanagementofactivepsoriaticarthritispatientselectionandperspectives AT beckkristenm tofacitinibinthemanagementofactivepsoriaticarthritispatientselectionandperspectives AT smithmaryp tofacitinibinthemanagementofactivepsoriaticarthritispatientselectionandperspectives AT orbaianamaria tofacitinibinthemanagementofactivepsoriaticarthritispatientselectionandperspectives AT liaowilson tofacitinibinthemanagementofactivepsoriaticarthritispatientselectionandperspectives |